Q2 2025 Abbott Laboratories Earnings Call
Good morning, and thank you for standing by.
Welcome to Abbott's, second quarter 2025 earnings conference call.
All participants will be able to listen only until the question and answer portion of this call.
Your touchtone phone.
This call is being recorded by Abbott.
With the exception of any participants, questions, asked during the question and answer session, the entire call, including the question and answer session is material, copyrighted, by Abbott.
It cannot be recorded or rebroadcast without Abbott's, Express written permission.
I would now like to introduce Mr. Mike Camilla, vice president investor relations.
Speaker Change: Good morning, and thank you for joining us with me. Today, are Robert Ford, chairman and chief executive officer and Phil budro, Executive Vice President, finance, and Chief Financial Officer.
Speaker Change: Robert and Phil will provide opening remarks following their comments, we'll take your questions.
Speaker Change: Before we get started, some statements made today may be forward-looking for purposes of the private Securities. Litigation Reform, Act of 1995
Speaker Change: Including the expected Financial results for 2025.
Speaker Change: Abbott cautions that. These forward-looking statements are subject to risks and uncertainties that may cause actual results to differ materially from those indicated in the forward-looking statements,
Speaker Change: Economic competitive governmental technological and other factors that may affect Abbott's operations are discussed in item. 1, a risk factors to our annual report on form, 10K for the year. Ended December 31st 2024
Speaker Change: Abbott undertakes. No obligation to release publicly any revisions to forward-looking statements, as a result of subsequent events, or developments except as required, by law.
Speaker Change: On today's conference call as in the past non-gaap Financial measures will be used to help investors understand Abbott's ongoing business performance.
Speaker Change: These 9, gaap Financial measures are reconciled with the comparable, gaap Financial measures in our earnings news release and Regulatory filings from today, which are available on our website at abbott.com.
Speaker Change: Note that Abbott has not provided the related gaap Financial measures on a forward-looking basis for the non-gaap financial measures, for which it is providing guidance because of the company is unable to predict with reasonable certainty and without unreasonable effort, the timing and impact of certain items which could significantly impact Abbott's results in accordance with gaap.
Speaker Change: Unless otherwise noted, our commentary on sales, growth refers to organic sales growth, which is defined in the press release issued earlier today.
Robert: With that, I will now turn the call over to Robert.
Robert: Thanks, Mike. Good morning everyone. And thank you for joining us.
Robert: At the half point halfway point of the year, we are on track with our key priorities and objectives. And the first half, we delivered High single digit sales growth.
Robert: Over 100 basis points of margin expansion in both gross margin and operating margin.
Double digit earnings per share, and we achieved a number of important, Milestones related to advancing Key Programs in our new product pipeline.
Robert: Our sales growth excluded Co testing sales with 7 and a half percent. The second quarter and 8% in the first half of the year,
Robert: our second quarter adjusted earnings per share of a dollar and 26 Cents, exceeded the consensus estimate, and reflects 11% growth versus the prior year and 16% growth on a sequential basis compared to the first quarter.
Robert: I'll now summarize our second quarter results in more detail before I turn the call over to Phil and I'll start with nutrition, where sales increased 3 and a half percent in the quarter.
Robert: Growth in the quarter was driven by 6.5% growth in adult nutrition were Abbott is the global market leader. We continue to see strong demand for our ensure and Glucerna brands in the markets around the world. And this growing demand is driven by consumers, seeking a source of complete and Planet balanced nutrition, especially for those focused. Um, protein-rich diets and media dietary requirements for managing diabetes.
Robert: Moving to Diagnostics sales decline 1.5% in the quarter predominantly due to the year-over-year. Decline in Co testing sales and the impact of volume-based procurement programs in China.
Together. These represent a projected headwind of around 700 million dollars or 750 basis points on the full year. 2025 sales growth in Diagnostics,
Robert: Excluding China.
Core lab Diagnostics, grew 8% reflecting, strong underlying demand in the markets around the world.
Robert: For the first time.
T15 markets, include India, China, and other markets across Asia, Latin, America, and Middle East.
Robert: These markets represent the most attractive areas of growth for Branded generic medicines.
Robert: The growth in these markets is supported by favorable, long-term Health Care, economic and demographic Trends, including higher birth rates and expanding middle class. Aging populations and growing demand for access to high-quality Healthcare Solutions. We serve this growing Demand by offering a broad portfolio of branded. Generic medicines tailored to local conditions with a focus on key therapeutic areas and additionally, we continue to make good progress toward building a best-in-class portfolio of Bio similars. Having completed 10 regulator approval submissions across a range of Emerging Markets with launches projected to begin in 2026.
Robert: And I'll wrap up with medical devices, where sales grew 12%?
Robert: Driven by double digit growth in Diabetes Care, heart, failure, structural heart electrophysiology and cardiac within management.
Robert: And Diabetes Care sales and continuous glucose monitors or 1.9 billion dollars in a quarter and grew 19.5%.
Robert: In April, we announced a first-of-its-kind collaboration with epic enabling direct integration of Libre. Sensor data into the leading electronic health record system,
Robert: This seamless integration allows Healthcare Providers to easily view their patients glucose Data before during and after meeting with patients supporting our goal of simplifying care to help deliver better outcomes for both Healthcare Providers and patients.
In Electro physiology, we got several key accomplishments in the quarter including delivering a number uh delivering another quarter of double-digit sales, growth initiating, the launch of our new volt, PFA catheter and completing enrollment ahead of schedule in our tactile Flex duo Us, pivotal trial.
In structural heart. Growth of 12% was led by a combination of continued, share, gains and tabber, strong adoption of triclip and contributions from amulet and mitro clip.
We achieved several important. Milestones, that demonstrate our commitment and progress toward expanding our portfolio of solutions to treat mitral valve disease.
Robert: As the leader.
As the market leader in micro Valve Repair, we continued to invest in the success of nitro clip. So, in addition to currently pursuing a label expansion to increase the addressable Market, we recently launched a Next Generation version of mitro clip. That further enhances the procedure with improved deployment and deliverability.
Robert: And to company our leading position in micro Valve Repair, we expanded our Focus several years ago to include the development of micro valve replacement Technologies. And in may, we announced FDA approval of our 109. Mitro replacement valve, which offers a new treatment option for those who are not candidates for open heart, surgery or mitral valve, repair procedure.
Robert: And that New York, New York, valves conference, a few weeks ago.
Robert: We provided an encouraging update on the development of our new Trans femoral mitro valve replacement product. We acquired this Innovative technology as part of our Venture Investments program, which led to the acquisition of Sephia valve Technologies in 2019 and following that acquisition. We continue to iterate and enhance the technology and the FDA recently, granted breakthrough designation. We plan to start the pivotal trial next year, and look forward to creating a new solution to help treat the world's most common heart valve disease, which impacts the lives of millions of people around the world.
Robert: And Rhythm management our strong performance as a result of our strategy. To build a comprehensive portfolio, capable of significantly outperforming the market and our own historical growth rates.
Our growth, this quarter of 10%, was led by strong, uptake of aair our Innovative leadless pacemaker which is driving growing adoption of leadless pacemakers in both the single and dual chamber of pacing, segments of the market in April, we announced late breaking data from The Av conduction system, pacing, feasibility study.
Robert: This was the first study to evaluate using a leadless pacemaker to deliver a conduction system pacing, which is a novel approach to pacing that closely mimics the heart's, natural electrical Rhythm. And following the successful outcome of this study, we are targeting to start the pivotal trial next year.
Robert: Include a double digit growth in ventricular. Assist devices, used to treat, both chronic and acute conditions and double-digit growth in cardumen. Are implantable sensor for the early detection of heart failure.
Robert: And Vascular growth of 3 and a half percent.
Robert: Was led by double-digit growth and Vascular Imaging and and vessel closure products, and increasing contributions. From a spree are below the knee resorbable spent. And lastly, in neuromodulation growth of 4% was led by strong performance of our Eternal rechargeable spinal cord stimulation device in international, markets reflecting. Both continued uptake in existing markets and launches in New Markets. So in summary
Robert: Our Diversified model continues to provide a strong Foundation. That is both resilient and designed to sustainably deliver top tier results now and in the future,
Speaker Change: And that's evident in our performance in the first half of the year which along with our outlook for the remainder of the year and the momentum heading into next year. Aligns with our long-term sustainable growth objectives of delivering High single digit growth healthy, margin expansion, and double digit EPS growth. I'll now turn over the call to fill
Thanks Robert. This is Mike mentioned earlier. Please note that all references to sales growth rates unless otherwise noted are on an organic basis.
Turning to our second quarter results, sales increased 6.9% or 7.5%, when excluding the covid testing related sales.
Speaker Change: Adjusted earnings per share of 1.26 cents increased 11% compared to the prior year and was above the consensus estimate.
Speaker Change: Foreign exchange had a favorable year-over-year impact of 0.5% on second quarter sales.
Speaker Change: During the quarter, we saw the US dollar a week in which resulted in a favorable impact on sales compared to exchange rates at the time of our earnings call in April,
Speaker Change: regarding other aspects of the p&l, the adjusted gross margin profile was 57% of sales which reflects an increase of 100 basis points compared to the prior year.
Speaker Change: Adjusted R&D was 6.3% of sales and adjusted sg&a was 27.7% of sales.
Speaker Change: Adjusted operating margin was 22.9% of sales which also reflects an increase of 100 basis points compared to the prior year.
Speaker Change: Based on current rates. We now expect exchange to have a relatively neutral impact on our full year reported sales, which includes an expected favorable impact of approximately 2%. On our third quarter reported sales
And lastly, for the third quarter, we forecast adjusted earnings per share to be in the range of 1.28 to 1.32 with that. We'll now open the call for questions.
Thank you. At this time. We will conduct the question and answer session. As a reminder, to ask a question, you will need to press star 1, 1 on your telephone. You will then hear an automated message. Advising you that your hand is raised.
To withdraw your question, please press star, 1, 1 1 again for optimal sound quality, we kindly ask that. You please use your handset of your speaker phone when asking your question. And again, that's star111 to ask a question. Please stand by we compile our Q&A roster.
Speaker Change: Our first question will come from David Roman for Coleman Sachs. Your line is open.
David Roman: Uh, thank you and good morning and I appreciate your taking the question here. Uh, maybe Robert you could start by just putting 2025 performance into context for us as I listen to the walk from the prior guidance, to the updated guidance. Um, I think it's pretty clear that it comes from some factors outside. The US in Diagnostics plus Co diagnostic headwinds, but maybe you could help us think through the headwinds you're seeing this year.
David Roman: The extent, which those are transient versus more permanent changes in the growth rate and what that looks like next year.
Robert: A sure David, uh,
Very well. Uh, 8% growth in the first half, building the biosimilar portfolio nutrition. Uh, first half about 5%, which is in the range that we've always expected them. Now that we've, um, you know, lacked a lot of the, uh, of the market share kind of recovery process here. So, really, the, the challenge that we've had, um, is, is is twofold here is really a drop off on our, on our Co testing sales, um, and and some challenges in in the China core lab, uh, Market together with some, uh, some changes that we've seen in the, uh, US foreign aid funding for HIV testing. So you, you you look at that and say, okay, um, I'm not sure these, These are impacts that are, uh, are 100% definite in the second half of the year, but I'm not going to sit here and try and kind of forecast. What Co testing is going to do, um, we had expected to see a China recovery and volume, renewed the price impact in China, Coral, lab.
Speaker Change: Uh, David, and we rolled that into our guidance, we had expected a, a market volume recovery to start happening in the, in the, in, in, quite frankly. Starting in Q2, we haven't seen that. So we've moved that out into, you know, into Q4. Um, but you put all that together. It's, you know, together with the US, uh, with the funding for HIV testing, uh, that's over a billion dollars of uh, uh I, I guess it's a headwind. And, and even with that a billion dollars, we're still, uh, we're still forecasting High single digit growth.
Speaker Change: and, uh, absorbing the impact of tariffs, which we now expect to be just just under million dollars, uh, of impact, um, FX, you know, as, as Phil kind of said in his comments is, uh, is uh,
Still a headwind versus prior year on the EPS side, but but much less of a headwind than what we had originally, kind of anticipated, uh, back in January and quite frankly people too. So that, that helps offset some of the, uh, some of the, some of the Tariff, uh, some some of the Tariff impacts. So, yeah, I put this all together and, uh, you got it, it'll be nice David to to, to, to, to lap these or, or or, uh,
To see these headwinds, uh, behind us, uh, next year. And then, as you look to next year, you got all this great, uh, launch activity, uh, across all the businesses. Whether it's vault in the US tactile Flex Duo internationally, uh, the, the Dual analyte sensor, the, the launch of the new alinity system, uh, the bio similar kind of roll out. So I look at all of that and I say, okay, you've got, you've got this headwind that we're facing here still, we're committed to high single digit growth, and double digit EPS growth. Um, and then, as you look into 2026, those headwinds aren't going to be there. And, uh, and then you've got all this kind of great momentum, uh, which I'm sure we'll talk about on another part of the business. So, I I looked at, uh, 2026. I look at and I know what the consensus are. Uh, they look very, very reasonable to me, um, in in that range of high,
Speaker Change: Every single digits double digit EPS. Uh, it's in line with our historical growth, it's in line with the guidance, we're giving this year and it's in line with, you know, what, our long-term sustainable growth targets are so, um, yeah, it'll be good to see these. Uh, you know, these elements here that I've just kind of highlighted, that are specifically to Diagnostics, and I'll just take it a step further here. I mean, if you look at our and I mentioned this in, in, in the opening comments here, uh, our core lab business outside and, and, and I hate doing this. Uh, but I, I think it gives context. Uh, if you look at uh, the US was, uh, you know, was up, uh, 778%, the European region was up 8% or Latin America region was High Teens. So our corelab business is doing very well. A lenity is doing very well, we just got this issue that, you know, we're going to have to go through, uh, this year, as it relates to vbp, and the disruption that happened in, in our core lab business in, uh, in China. But we're we're still very bullish on, uh, on this segment. Uh, we still believe it's a very important part of the Healthcare System.
Speaker Change: System. Um, so like I said, looking forward for these headwinds to be behind us and, um, and um, we're well set up for next year.
David Roman: That's very helpful. Maybe they just push a little bit harder on on 1 point there. If I look at the guidance for this year, it's really kind of 8 and a half percent. When you take out some of those 1-time, headwinds 1 thing you didn't mention was obviously an EP you face a little bit of a portfolio Gap this year and that looks to fully resolve as you head into the back half of the year and into next year. So is there a scenario?
David Roman: Area in which we could see some of these 1-time, headwinds reverse and, and see the growth rate accelerate into 2026 and uh, correspondingly. See that fall through to the bottom line, recognizing its early to talk about 26. But just conceptually, uh, some of these headwinds fading and some of those pipeline drivers starting to kick in more significantly. Yeah, this is
David Roman: Early to kind of put a put a, you know put a full stop on that, but there's definitely opportunities across the portfolio, which we'll talk about. Uh, likely that said, hey this, you know, you mentioned electrophysiology. I mean, that's been 1, that's been 1 part of our portfolio that, uh, has consistently. Um, you know, kind of exceeded the expectations, both the expectations, quite frankly, that you guys have had and the expectations that we've had. So, so, yeah, I mean, there's definitely opportunity as these reverse out, uh, to see that uh acceleration. Maybe a little bit early to say that, but right now, in terms of where we're sitting for 26, I feel very comfortable with that.
Speaker Change: Excellent. Appreciate your taking the questions and bearing with me here as I have a cold today. Thank you.
David Roman: Yep.
Speaker Change: Thank you. Our next question will come from Robbie Marcos from JP Morgan. Your line is open.
Robbie Marcos: Oh great. Uh good morning. Thanks for taking the questions um 2 for me I'll I'll ask them both up front, both product questions. Um
Speaker Change: Diabetes and EP, uh, both performed really well in the quarter, um, particularly us Libre. Uh, it was good to see us double digit EP. Um, maybe just walk through some of the trends you're seeing in, in each of those product lines, uh, especially in diabetes. There was a lot of Buzz, uh,
Speaker Change: Around Ketone integration.
Speaker Change: And and that product coming from Abbott. Uh, so what are you seeing in in diabetes? And then also uh, EP especially now with vaults launching outside the US, thanks.
Speaker Change: Uh, for Robbie, uh, yeah. Another another great quarter of Libre um, uh, almost 26% in, uh, in the US, uh, an acceleration internationally also, uh, I think all 3 segments we're seeing great momentum. So if you look at intensive, uh, the Intensive insulin user segments, um, you know, obviously that's been a key growth driver for the market. Uh, but there's still, uh, you know, there's still segments there that are underpenetrated and, uh, we're seeing nice, uh, nice growth in there. And, um, you know, the the, the, the, the, the, the new sensor you reference I think is going to is going to definitely accelerate their the basil segments doing very well. Uh, big growth driver for us still, um, market leader here, our, our, our view globally is we've got about a 70 share. Um, you know, you know, some of the markets that have kind of began reimbursing for Basil, uh, Robbie. Uh, we're starting to see, uh, more, uh, markets, uh, go down this path and, and start reimbursing basil.
Speaker Change: Whether it's like specific tenders and regions or or uh, or or different, uh parts of Healthcare Systems. So so that's good and we see like sustainability to that growth rate and our position in those in those International markets. And then, you know, the the non-insulin user segments doing very well. Very nicely to, I mean, I think, uh, right now you've seen, uh, commercial coverage for the United States. Uh, I'd say around about 30% is what we're seeing, uh, and that's doubled over the last 3 years. So um, so I think the trends are the trends are doing very nicely there. Um, and. And I can see that, you know, continuing for the foreseeable future as part of our of our 10 road to 10 billion uh in Revenue. Um your your your your question on uh or at least your comment on the uh the Dual analyte sensor I think this is going to you know this is going to be a I think a real Next Level kind of. I'd say significant change in the CGM Market, specifically for the Intensive users. Um,
Speaker Change: You know, Ketone monitoring helps prevent uh, diabetic key. So ketoacidosis we have a legacy of being in that, you know, we were the first company to, to develop a blood test, a rapid blood test for that, um, you know, many decades ago. So we know how important it is. It could be life-threatening. Um, you know, the the 88 conference you referenced. I thought there was some interesting clinical data that showed 30, I think it was 30% of pediatric patients in 40% of adult. Participants, uh, saw like, uh, in this trial saw like increase Ketone levels,
Speaker Change: That put them at risk, um, if there was an interruption on on insulin delivery. So uh, so there's clearly a need, uh, for this patient segment. Um, I think you saw that all the announcements that came out during the conference with all the pomp integration. So there's clearly a need there. It's understood. Um, and, uh, an opportunity to expand even further. Um, we know that, um,
Ketone monitoring here is going to create a path.
And I think that our position is just going to be strengthened even more, um, as uh, as we bring out, uh, you know, the Innovation. Um, and, um, so looking forward to that, I think on your question, on, on EP. Um, yeah, we saw, uh, good, uh, double digit growth in EP, this quarter, um, double digit growth last quarter.
Speaker Change: Um, saw an acceleration in the US growth rate of this quarter versus last quarter and, uh, a lot of attention now, shifting towards, uh, rolling out of uh, of volt.
To the international markets, we tend to like we like to launch our products in a in a more kind of limited fashion. So when you move, when you move from um you know, clinical trials to full-out launch, we like to have this little period in between here Robbie where we we we get to just to put it out, uh, in a little bit more of a, an environment that we can. Just make sure that, um, you know, we're, we're clearly understanding and, and getting all the feedback in a more, uh, direct fashion. And when you go, when you go a little bit more focused, uh, you get uh, great opportunity to do that. Uh, so really focusing right now on the, on the, on the sites that were enrolled, uh, that were enrolled in in our trials and, and the feedback's been excellent. Um,
Speaker Change: Um, I think that, uh, it Stacks up very well versus competitors. I, I think the balloon design, uh, is perfect for pvi, uh, I think it optimizes, uh, a lot of the process. And if you think about where, uh, those, uh, you know, prior balloon based systems were used in Europe. I think this fits very nicely there, uh, but its efficacy is great. Uh, parasym data is is Best in Class, um, as we said during, um,
Speaker Change: During the period. We were talking about the development of Vault. Uh we believed in uh in mapping and uh and contact and visualization of contact. And I think that's what we're seeing for from these early cases here just providing really real time feedback on tissue contact. You know that leads to you know, fewer applications leads to fewer, you know, less fluoro time less to lead to less muscle contraction which I think is really important. If you think about some of the segments globally that are going to start to really, you know, Advanced, um, in terms of market segments, segments, that will, um, you know, benefit by having a procedure that could be done without general anesthesia and just with General sedation. Um, and I think that uh, I think Vault fits very nicely into those segments there too. So, um, so so far so good. The team's doing a great job. They've been doing a great job of the last couple of years and uh I think they're excited now to uh, to transition to this phase of the strategy now, which is not
Speaker Change: Now that we've gained a lot of market share with mapping, uh, and it's not to bring in the uh, bring in the, uh, you know, the PFA CA that we think is, uh, is very competitive.
Speaker Change: Appreciate it. Thanks Robert.
Speaker Change: Thank you.
Speaker Change: Our next question will come from Larry biegelsen from Wells, Fargo. Your line is open.
Uh, good morning. Thanks for taking the question, Robert. Um, I just wanted to ask 1 uh, follow-up question for multi-part follow-up question on Libre. So, uh, first, I'd like to get your reaction to the proposed competitive bidding for CGM and and what that could mean for you. Uh, second, the RFK Junior comments on wearables, do you think that could accelerate type 2, non-insulin CMS coverage and just lastly on the Dual Ketone sensor? Um, do you think that could drive share gains for you in in intensive uh insulin patients where your share is lower? Thank you.
Speaker Change: Sure. So
starter, um, so on
Speaker Change: Contracted, uh, in the CIA Mass proposal document here, I don't think there's a, uh, any major changes as it relates to, uh, CGM. Um, it's cmf chooses to do competitive, you know, to go down the competitive bidding route. Uh, it's really going to be the dmes that are going to be the ones doing the bidding not. Not the CGM, manufacturers. I think this is probably going to take, um, a couple of years to fully implement the process. And, you know, I don't expect, I don't expect there to be an impact on, on, on Abbott, but we're going to
We're going to continue to Monitor and and as I've said um in in other situations, 1 of the things that we've got to keep on doing here is to be the leader of scale leader of cost. Um and uh so you know, we'll continue to Monitor and uh we'll be ready.
Speaker Change: Um, your other question was regarding, uh, the comments from the Secretary of HHS, uh, regarding wearables. Um,
Speaker Change: Significant impact on, on 1's health. And, uh, and so, um, I think you can keep your glucose levels in a healthy range, it offers a lot of benefits, there's lower risk of diabetes heart disease. Uh, it helps with weight loss. We've seen that, um, improves productivity, Etc. So, I I appreciate, uh, the secretary's efforts here to, to, to, to promote, uh, improving the health and wellness of all Americans. And I, I think that's in line with, uh, with our company's Mission, um, and um, certainly supportive, uh, of this initiative. Um, you know, we would help we would hope that, uh, uh, that it would be, uh, Americans wearing cgms that were made in the United States. We have 2 manufacturing sites. Uh, but uh, anyways, we, we, we support that initiative. Um, and then
Speaker Change: I think your question was, uh, regarding uh, uh, the continuous glucose Ketone sensor. Do we think that that can accelerate our share again? 100%? Yes.
Speaker Change: Clear very clear. Thank you.
Speaker Change: Thank you.
Our next question will come from Vijay Kumar with evercore isi. Your line is open.
Hi, Robert. Good morning, and thanks for taking my question. Uh, I had 1 a product related and 1 up p&l question on, on the product side, uh, of your CRM is doing really, really well, um, how I guess, uh, are there any metrics you could share or not? What, um, what percentage of your installed base has been updated or converted to of your, uh, where are we in, in the, in the conversion cycle? And, uh, and is it now?
Speaker Change: Like a double digit or team. So, for the foreseeable future. What do you think is the ultimate time for this uh kind of product is
Speaker Change: I think it's fundamentally changed the uh, the growth, the growth trajectory of our CRM business. And now you're trying to ask yourself, okay. Is this a 1-off thing or or or or or can we can we Bank on this? If you look at the trajectory of our CRM business, uh, 2023, when we launched single chamber, our growth rate was 7%. Um, 2024 it was 7%, uh, first half this year, it's 8% shown 10% growth this quarter. Um, I think that uh achieving this uh is is is very sustainable. Um, you know, I talked about what we wanted to do with here uh with a ver in the past, you've got a 4 billion dollar Global pacing Market that really hasn't seen much Innovation uh VJ and
Speaker Change: wanted to do was to really make sure that as we rolled this out, we weren't just looking for a kind of a, a niche, uh, kind of, you know,
Speaker Change: Jump in sales and, and then, and then that's it. So, we team has done a really good job here in terms of coordinating between marketing and clinical and sales. And uh, I think these teams have now really gotten full, you know, are really aligned, I think they're really hitting their stride here to be able to, uh, look at expanding, uh, the not just in the US, but also internationally. So, uh, I, I think it's the work that they're doing here to be able to get Physicians, trained and hospitals set up. And uh, it's a little bit of a different implant procedure so do so you do need to go through that. But we, we took our time to do this and do this, right? And I see, I think we're seeing the the benefits here of of of of taking that time to do it, right? I think it's really driving uptake. Uh, not just in, uh, not just in single but without a doubt in in dual chamber. So we're seeing an increase in uh, in the number of accounts. Uh, from a year ago. Um, we've seen an increase in uh, the amount of
Speaker Change: Physicians that have been trained. That that's increased like, by 50%. I think it was the last time I saw it. Uh, the implants per day have doubled as a result as a result of that. So I think it's going very well and I think I expect to see this outer performance continue here. Uh, and then the next kind of several years um, 1 of the things that we're also doing to kind of be able to
Speaker Change: report that and I said that in my prepared comments was um,
Speaker Change: um,
Speaker Change: 2 years. Some of them were just in the process of launching. So I think there's a lot of good momentum here, uh, with this portfolio, not just in terms of, uh, you know, execution out in the market but also, in terms of R&D and clinical work,
Yeah, that's helpful. And maybe 1 on the EPS guidance here. Um, the the um,
Speaker Change: Top in was lowered by 5 cents in the midpoint was maintained despite despite I think um, operating margins tweaked down, um, organic coming down.
Speaker Change: Uh, where are the offsets here? You know, maybe some some comments on what is underlying operational, uh, versus, uh, perhaps change in FX and tariff assumptions
Speaker Change: Now that still take that 1.
Yeah. Thanks uh VJ uh, uh very quickly here Robert touched on some of the sales drivers and kind of de-risking elements there. Um, and we also touched on kind of the FX impact going forward at current rates, at least and and kind of that, uh,
Relationship. That's not a 1 for 1. Fall through just kind of the mechanics of of how inventory moves through the system. And, and the like, so while there's a neutral Top Line impact, there's still a headwind both year-over-year uh, as Robert touched on, in his opening comments, that's still a headwind on, on the bottom line here, uh, along with kind of tariffs kind of rolling in um,
Speaker Change: Second half of the year as those work their way through inventory as well. So those are the the elements of of D risk and then uh, kind of
Speaker Change: Normal. Headwinds.
Speaker Change: Sorry. Could you quantify which uh what was tariff contribution versus operational FX?
Speaker Change: Yes, so I think Robert mentioned tariffs are, you know, a little less than 200 million here. So down from, uh, from previous estimates and then the FX impact here, I think, over the last several years. If you look at it on average, we face on average about a 4%, EPS headwind on the bottom line, uh, and that kind of moves, uh, as currencies will and do uh,
Speaker Change: With factors on on inflation and interest rates, and the like, but uh, you know, we're in that same realm of impact, a little less than that. That historical 4%, but certainly, uh, year-on-year negative impact, uh,
Speaker Change: So roughly a nipple.
Got it. Thank you.
Speaker Change: Thank you.
Speaker Change: Our next question will come from Travis Steed from BFA, security. Your line is open.
Speaker Change: Hey, thanks for taking the question. Uh, first question. Uh, it was on m&a, just kind of curious. Uh, how you're seeing the pipeline shake up and Diagnostics and Medtech. And if you could see Abbott, do a more sizable uh transaction this year on the m&a side and then it, it sounds like on on EPS like you're comfortable with the 3 consists of uh double the gdps growth next year.
Is that assuming terrorists at the current rates or do you have a lot of some p&l flexibility next year, as well as tariff rates move with it from here?
Speaker Change: Sure. Uh what was the first question again?
Speaker Change: Uh, oh m&a uh m&a, um, yeah. Uh, yeah. It's a, it's a, it's a, it's a good environment, uh, for, uh, for you know, for m&a. Um, good opportunities out there, got a strong organic pipeline, so that allows us to be a little, a lot more selective here. It was, seeking the opportunities that will fit our strategically and going to generate and attractive return. So, um, not looking just to acquire business to to, you know, to make our Top Line larger here. You know, the profitability, as I've said the earnings, the roic that all matters to us. So, um, and then, um, your question on EPS, uh, for next year. Does it include, um, FX. Well, listen. There it includes what we know right now. Uh,
Speaker Change: Travis. And, you know, those, you know, as, as we're all going through they could they can change. Um, they can kind of move around, um, but as I said, in the call in April, you know, our goal here is is, is not to use, you know, focus on, you know, mitigating items that would cause a year-over-year kind of impact. So, you know, we didn't go out and build a bunch of inventory, you know, over the last couple of months.
Speaker Change: Uh, we're going to build another cardiovascular manufacturing site here in the US, uh, and and began that process also. So we're thinking about it, uh, once tariffs get in set in place, um, they're very difficult to walk away from, uh, so we have to think, also medium-term, but also long term. So, um,
Great. Thanks a lot.
Speaker Change: Yeah.
Thank you.
Speaker Change: Our next question will come from Danielle and toffee from UBS. Your line is open.
Danielle Toffee: Good morning guys, thanks so much for taking the question. Um, Robert I actually just have, I'll keep you to, to 1 product question. And that's within within that Tech specifically, structural heart, I mean, you guys have been launching amulet for a while now. And we have a, a pretty potentially a big game-changing trial readout coming for your competitor early. Next year, which to me feels like a rising tide full of salt boats situation potentially. So, I'm just curious looking at the structural heart, uh, consensus estimates for, for next year, modeling deceleration. I mean, I just have to imagine that that could actually accelerate uh, amulet growth and I would just love to hear your thoughts on how you're thinking about that and the potential Tam expansion that I think would be a class affect uh, for both uh both devices.
Danielle Toffee: That are on the market today and sort of how you're you're factoring that into the long term outlook here for the structural heart business. Thanks so much.
Speaker Change: Sure. Well, I mean, I so yes I conclude with all the things you've been talking about their as this is a, a very important kind of growth opportunity, uh, that we see, uh also um uh competitor is um, uh, is is going to has been investing in a trial, uh, that could potentially expand the market. So, are we? Uh, so we have our own trial here. I think it's going to be important, uh, to have the data to be able to kind of support your product. So we've made that investment, uh, we should complete enrollment in our trial, um, this year and um, and, and then, you know, um, like I said, if if, if these are all great trials and positive trials, I think it's going to have a, a big impact here, in terms of our ability to, uh, to to expand the market. Um, our job also, you know, we're not, we're not the market leader. So we have things that we also have to uh, address. So we've spent, uh, a good amount of R&D.
Speaker Change: Money, uh, Danielle to make sure that, uh, we can, you know, accelerate here our second generation, uh, device and, um, you know, we're enrolling in that pivotal trial. Um, I'd say what we were trying to resolve there was, uh, or or improve upon is, we've got great. Uh, we got a superior ceiling.
Speaker Change: Uh, capability. And we've got this much broader range of, um, you know, ability to hit a lot of different types of inanimate, uh, anatomies. Um, but 1 of the feedbacks that we got is like, can you make it easier for deployment? And, um, and delivery. So, uh, teams have done a really good job with that, the feedback that I have gotten, not only from my team, but also from the Physicians that are enrolling in, in our trial, for this next Generation product has been spectacular. Um, very positive on those issues that we were trying to improve upon. So, um, so we look, we we think this is, uh, a, a very strong opportunity for us, you know, tying in with our, you know, with our EP, uh, and aib procedure. Uh, we know there's a growth and concomitant procedures here too. So, I think that this is, uh, this is a, an important growth driver, uh, for us. Um, and uh I I share your view.
Speaker Change: um, and I think that, uh, our product here, uh, is very competitive and it's going to become very, very competitive, uh, as as we launched the second generation,
Speaker Change: It's for that.
Speaker Change: Thank you.
Speaker Change: Our next question will come from Josh Jennings from TD. Cowen, your line is now open.
Josh Jennings: Hi, good morning, thanks for taking the question, wanted to just uh ask about your table or franchise, um, and maybe Robert, if you could help.
Speaker Change: Or share your your expectations for for market growth here.
Speaker Change: A quick nuanced, if you, if you can talk about anything that you're seeing in Europe with the Boston exit and and Navajo uptake, or sh share games from that competitor event would be great. Thanks for taking the questions.
Speaker Change: Sure, uh, well listen, we wanted to be, uh, our, our vision, uh, here is to be the leading structural Health, uh, structural heart company. Uh, Global structural heart company, and the only way you can actually do that, is to really have a full portfolio of products here. Um, and uh, obviously, I've talked a little bit about my comments about my troll. Um, we've made the investments in the tricuspid area and making the investments in in, in the tabber side too. So, specifically on tabber, uh, an AER continues to get a lot of positive feedback from, uh, from The Physician. That's a very, it's a very compelling offering. It's a excellent involved design, easy to implant, uh, it got great clinical data, um, our sales have doubled over the past, uh, 2 years, uh, the Big Driver of that I would say over these past 2 years has been International, has really been the driving Factor here of success, and I, I expect that to continue. Uh, there's an opportunity here to, uh, to accelerate
That growth, uh, internationally with a with a competitive, uh, uh, competitor Market, exit. Um, I know the teams all over that. Um, and, um, with the upcoming CE Mark that we have planned for navtor to have low and intermediate risk, label expansion. Uh, it couldn't come at a perfect time, uh, to be quite honest with you. So, um, so I expect that to continue and accelerate for us, uh, Josh, uh, and then we're building our position here in the United States. And, you know, right now we're in about 20% of, uh, of of the centers in the United States. And, and the way to the way to expand our our position here is we, we got to be in more centers. And the way to do that is you need more, you more need more clinical people, you need more feet on the street, uh, and that's what we're doing. So, we've actually, we will be doubling the size of our team, uh, and I'd say, putting ourselves in the realm of being more competitive, in terms of access to sites,
Speaker Change: Uh, by the end of this year, we'll have doubled it versus last year. And, uh, and there's a, there's a normal ramp up in terms of rep productivity that we know in this space. So, you know, all the people that we've been adding, um, I expect that to now start to really have a nice impact as we go into 2026. Um, it's definitely a competitive space. There's no doubt, but I think here between the commercial Investments we've made, um, in the United States, uh, the opportunity we have with label expansion and, uh,
Speaker Change: Um, um, and comp, and just like a market disruption and international markets. I think that, you know, is a is a, is a till win for us to their. Um, and then, you know, once you once you commit yourself to developing, you know, next Generation kind of balloon expandable power, that that also opens up a nice opportunity for us even though that'll probably be. Um, you know, more towards the end of this decade in terms of full launch. Uh, but it does help, uh, as you're rolling out, you know, all these strategies that I've talked about. So, uh, so we feel good about the TA teams doing a good job, um, like them to do better, uh, but um, you know, so far so good and um, and there's a lot of good momentum for us on this business.
Speaker Change: Appreciate it. Thank you.
Speaker Change: Thank you.
Speaker Change: Our next question will come from Adam Mater from Piper Sandler. Your line is open.
Hi, good morning. Thank you for taking the questions. Uh, 2. Quick ones for me. I'll ask them both up front. Uh, Robert first was hoping for an update, uh, on instant formula litigation and the mdl process and how you think about potential, uh, Pathway to resolution from here? And for the second question, um, Wanted just to go a little bit deeper on the Dual analyte sensor. Um, you know, specifically around expected approval and launch timing, is that first half, 26 pricing strategy, and how quickly you'll integrate with the different pumps. Thank you for taking the questions.
Speaker Change: Um yeah sure. Uh listen I'm not going to comment specifically on any kind of upcoming case uh regarding uh the neck litigation. Um, I'm going to
Behind it. And and kind of issued statements about about the product. And, um, you know, we're, we're going to stand behind it. Um, if we need to take action, um, on the product and, um, you know, that like like I've said in the past, uh, it's a small part of our Revenue, um, and if we have to, uh, take action on, on, on, on the availability of that product. Uh, we will, um, if you know, if the science is not respected, if the regulatory process is not respected, if the medical community is not respected. Then you know, it it's going to be difficult to keep that product on the market. But uh, so far, I I think there's been a lot of support, uh, from the Physicians and from The Regulators, um, a lot of support from, um,
From, um, you know, variety of different stakeholders, uh, to want to see, uh, you know, this resolved and, uh, and, and this product remained on the market and ultimately, you know, those making, uh, the decisions on how to feed. Uh, the most vulnerable of, of the American citizens here should be Physicians and unintelligible. And and, and, and, and not, you know, not lawyers in courtrooms. So,
Speaker Change: And then, sorry, what was your second question?
Sure, the second question was just a couple follow-ups on the, the Dual analyte sensor, um, wanted to just better understand, expected launch timing in the United States.
Speaker Change: If you're getting you know any color around pricing strategy and just how quickly you'll integrate with the different uh pump players. Thank you. Okay. So 3 questions there on timing, I'm not going to, I'm not going to talk about timing of that. Um, I'm not going to talk about, you know, when, when we've submitted how we've submitted, uh, I'll I'll say is that this is a first time that that you'll have a sensor that will measure continuously 2 different analytes. So we've done a lot of clinical work. Uh, approximately 5 different trials to be able to support its submission. And we've, we've already completed those trials. So, um, so I'm not going to give uh, I'm not going to give timelines as to when the products out. Neither am I going to give, uh, any any details on pricing? Um, and and how we will think about pricing, uh, but as it relates to integration, um, you know, 1 of the reasons we we wanted to, um, you know, line up, uh, you know, have the conversations with, you know, with the different insulin,
Speaker Change: Uh delivery, uh, pump companies to make sure that, you know, when we do have it approved, um, that it will be, uh, available as quick as possible, for that for the population. So, as you saw during, uh, during uh, the uh, the Ada there were, there were some announcements over there. And I think that's, you know, that's, that's a little bit of the strategy behind that. So,
Speaker Change: Thank you.
Speaker Change: Thank you.
Our next question will come from Matt. Mix from barklay. Your line is now open.
Hey, uh, thanks so much for taking the questions. Um, I know we've covered a lot of the, the products and, and, and some of the key elements of the quarter and and the guide, um, maybe just a couple of quick follow-ups, um, 1 on on m&a. Um, I know you're remaining important part of your part of your strategy. Um,
Love it. If you could share any color as to kind of where you see, uh, the most, you know, next most likely kind of Investments or where you think there are kind of gaps in the, in the, in the, uh, in the portfolio. You'd like to fill whether it's tricuspid or or any Diagnostics or across the board, uh, be super helpful. Thanks.
Yeah. Um I I get that people always like to triangulate. I'm not going to I'm not going to tell you, I'm not going to Telegraph where we're going, but I I mean I've been pretty clear, it's Diagnostics. It is uh it is uh devices. Um those are the areas that are of interest to us. Like I said, there's a lot of uh there's a lot of um um opportunity in both those areas. And uh we'll just continue to apply the framework that we've always applied to when we do. Um m&a which is a belief that can we make these, can we make these assets better? Can we bring them to more people? Can we bring care to more people as a result of them? So um,
Speaker Change: I I don't, I don't think I've got more to add, uh, uh, on that Matt. Um, you know, like I on top of that. Um, like I said, we've got great growth rates here right now across the businesses. And, um, so again that puts us in a space where we can be a little bit more selective.
Great. We'll leave it there. Thanks.
Speaker Change: Okay.
Speaker Change: Operator. We'll take, uh, 1 more question, please. Thank you. And our last question will come from Murray thy Bolt from btig. Your line is now open.
Speaker Change: Biosimilars, uh, on the market soon, wanted to get a little more detail, on how to think about, kind of the reach of those products. Um, the Investments needed on your end, maybe an sgna and things. Um, and um, you know, the size of some of those markets that you're trying to reach. Thanks for taking the questions.
Speaker Change: Sure. Um,
Speaker Change: this is an
Speaker Change: opportunity for us to really. Look at how
Speaker Change: Growth rate in this.
This is a business that uh has been growing, you know, between 8 10%. Um it's it's learned uh through a very uh very strong management team how to manage through kind of FX cycles and inflation in markets. So they've been able to expand margins. So this is about how do we do this in a capital efficient way uh to bring more assets uh to uh an an existing infrastructure? That's pretty well set up Marie between the sales force that calls in the doctors that calls on uh, retail distribution. Uh, the teams that we have in place that work with, uh, government agencies and Regulators. So, so the infrastructure in place is there. Um, do I do? I think that there's, uh, there there will be some need to, to add some sgna to be able to, um, you know, educate the market because this is a very underpenetrated Market when it comes to biologics. Um, so there is some, there is some sgna involved in that
Speaker Change: That, but it's not like this, you know, you're really taking advantage of the infrastructure and the and the scale that you have in these markets across different channels and Regulators to be able to add in uh, add in this. So um, so I think we'll leverage our existing presence in these Emerging Markets, we're going to bring these Cutting Edge medicines into these countries that I say that historically lack the access. The predominance of the disease is or, or just as large or, you know, from a percent perspective than they are in in the developed markets. And um, you know, if you look at the portfolio it will look it. You know that we we've made. We've looked at where the areas that we think will be of interest. So autoimmune disease. Uh, Women's Health oncology access to glp owns. Um, so, you know, so we the team has really done a good job here, laying in here, a real nice pipeline of products. And, um, you know, as I said, we're going to, we're going to start launching. Um,
Speaker Change: You know, in a, in a small Market this year and then we'll start rolling them out. Um, you know, obviously as um, as they become uh, from a regulatory perspective available to us, we'll be rolling them out next year and I think this can be a nice contributor here to our growth in this business uh, in the next few years.
Okay, um, well listen. Um, I'm I'm I'll just a few comments here to close. I'm, I'm pleased with what we've accomplished in the first half. We've, uh, delivered High single digit sales growth and and double-digit EPS, we've expanded our gross margin and operating margin, which is something that, you know, we've committed to and we've talked about and we've done it by about 100 basis points, you know, the second half, uh, sales growth guidance is de-risked to account for some, uh, some of these items here that I, I consider to be a little bit more transitory that are specific in the diagnostic space and uh, we're going to be lapping these next year. Uh, that's still leaves. You know, 11 plus billion dollar Revenue, quarterly Revenue growing a high single digits, uh, throughout the rest of the year. And um, and and on top of that, we've reaffirmed our guidance, despite some of these headwinds and and the impact of tariffs. So I think this is another great example of how our Diversified model continues to provide, you know, that strong Foundation. It's resilient. And it's well positioned.
Speaker Change: To.
Speaker Change: Uh, to deliver, you know, top tier results. Um, so, uh, we've got good underlying momentum here. That um, I'm very confident, we'll carry into next year. So with that, I'm going to wrap up and thank you for joining us.
Speaker Change: Thank you, operator. Thank you all for your questions. This now concludes have its conference, call a webcast replay of this. Call will be available after 11:00 a.m. Central Time today on Abbott's investor relations website at Abbott investor.com
Thank you all for joining us today.
Speaker Change: Thank you. This concludes today's conference call. Thank you for participating. You may now disconnect everyone have a wonderful day.